You just read:

BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study

News provided by

BioMarin Pharmaceutical Inc.

Nov 14, 2019, 08:27 ET